Opinion on Central Nervous System in France

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Targacept: potential shift in research focus for ADHD candidate

Targacept's investigational neuronal nicotinic receptor agonist has failed to meet its primary endpoint in a Phase II trial in adults with attention deficit hyperactivity disorder. Datamonitor expects that future development focus for TC-5619 will shift towards schizophrenia, in view of Phase II data demonstrating efficacy in the treatment of cognitive dysfunction associated with the condition.

Published By Datamonitor
25 Mar 2011
ResearchWire
ResearchWire

Stroke: UK has lowest usage of CT brain scans

Published By Datamonitor
18 Dec 2001
ResearchWire
ResearchWire

Schizophrenia: suffered by 1.3% of world population

Published By Datamonitor
27 Jun 2001
CommentWire
CommentWire

Sanofi-Aventis: slimmer pickings for Acomplia after FDA knock back

Sanofi-Aventis has received an approvable letter from the FDA for Acomplia for its weight management indication and a non-approvable letter for smoking cessation. Although it is still unclear how long a launch in weight management will be delayed, the news has already prompted a fall in the company's share price, as investors fret over the drug's prospects.

Published By Datamonitor
28 Feb 2006
ResearchWire
ResearchWire

Parkinson's Disease: sales of COMT inhibitors will more than double by 2007

Published By Datamonitor
21 Mar 2001
ResearchWire
ResearchWire

Pain: on the increase

Published By Datamonitor
19 Mar 2001
Expert View
Expert View

Ovation Pharmaceuticals' Sabril recommended by FDA panel despite reports of visual field defect

Ovation Pharmaceuticals has announced that an FDA advisory committee has voted unanimously to recommend Sabril (vigabatrin) for the treatment of two severe forms of epilepsy. If approved, Sabril will be the first FDA-approved monotherapy for infantile spasms. However, low historic uptake in the EU and concerns regarding visual field defects suggest that the drug's commercial prospects are limited.

Published By Datamonitor
12 Jan 2009
CommentWire
CommentWire

NicOx/AstraZeneca: a new class of pain medication

NicOx's HCT 3012 is a new class of analgesic and anti-inflammatory drug, with a superior gastrointestinal safety profile compared to naproxen. With AstraZeneca's backing, this product has the marketing strength to compete with Pharmacia and Merck - who currently dominate the non steroidal anti inflammatory drugs (NSAID) market.

Published By Datamonitor
23 May 2002
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002
ResearchWire
ResearchWire

Multiple sclerosis: new treatments will take on interferons

Published By Datamonitor
14 Mar 2001

« | 1 | 2 | 3 | » »|

No help is available.